Amgen sales rose by 5% in Q1

Share this article:

First-quarter Kyprolis sales of $68 million helped increase Amgen's first-quarter sales by 5% compared to the same period last year.

While the biotech saw increased demand and sales for drugs, including bone biologic Prolia and anemia product Epogen, demand and sales declined for some brands, with sales of RA shot Enbrel slipping 5% and kidney drug Aranesp sales falling 2% compared to the same period last year. The company attributed some of this fall-off to inventory draw-down.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.